Startseite>>Signaling Pathways>> Neuroscience>> COX>>Teriflunomide impurity 3

Teriflunomide impurity 3 (Synonyms: 4-Amino-N-(4-trifluoromethylphenyl)benzamide)

Katalog-Nr.GC61764

Teriflunomid-Verunreinigung 3 (4-Amino-N-(4-trifluormethylphenyl)benzamid) ist ein selektiver COX-1-Hemmer mit einem IC50 von 30 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Teriflunomide impurity 3 Chemische Struktur

Cas No.: 1011244-72-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
52,00 $
Auf Lager
5 mg
46,00 $
Auf Lager
10 mg
83,00 $
Auf Lager
25 mg
158,00 $
Auf Lager
50 mg
260,00 $
Auf Lager
100 mg
417,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective COX-1 inhibitor with an IC50 of 30 µM. Teriflunomide impurity 3 is less active against COX-2 (IC50>100 µM)[1].

Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide; compound 11q) is an amide-bond-reversed compound bearing trifluoromethyl and amino substituents showed potent COX-1-selective inhibitory activity[1].

[1]. Hiroki Kakuta, et al. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem. 2008 Apr 24;51(8):2400-11.

Bewertungen

Review for Teriflunomide impurity 3

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Teriflunomide impurity 3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.